Table 2.
Clinical characteristics of the patients.
| Variable | T2DM-0 group (n = 20) | T2DM-MC group (n = 17) | t/X2/Z | P |
|---|---|---|---|---|
| Age (years) | 57.20 ± 7.44 | 62.00 ± 6.91 | 2.02 | 0.051 |
| BMI (kg/m2) | 24.30 ± 3.97 | 25.70 ± 2.91 | 1.203 | 0.237 |
| Family history (%) | 10 (50%) | 7 (41.18%) | 0.288 | 0.591 |
| HbA1c (%) | 8.48 ± 1.25 | 9.34 ± 1.26 | 2.091 | 0.044∗ |
| FBG (mmol/L) | 7.23 ± 1.88 | 8.35 ± 1.51 | 1.788 | 0.082 |
| 2hPG (mmol/L) | 12.49 ± 2.98 | 13.92 ± 2.78 | 1.007 | 0.321 |
| Hypertension (%) | 12 (60.00%) | 11 (64.71%) | 0.087 | 0.769 |
| Hyperlipidemia (%) | 13 (65.00%) | 12 (70.59%) | 0.266 | 0.606 |
| CRE (μmol/L) | 50.05 (43.00, 57.08) | 60.4 (47.42, 85.69) | -1.417 | 0.156 |
| Diabetic macrovascular complications | 1 (5.00%) | 2 (10.00%) | 0.564 | 0.452 |
| Medication status of antidiabetic agents | ||||
| Metformin (%) | 18 (90.00%) | 14 (82.35%) | 0.46 | 0.498 |
| α-Glycosidase inhibitor (%) | 5 | 4 | 0.011 | 0.917 |
| Insulin (%) | 13 (65.00%) | 13 (76.47%) | 0.579 | 0.447 |
Abbreviations: T2DM-0: no diabetic microvascular complications; T2DM-MC: diabetic microvascular complications; BMI: body mass index; HbA1c: glycated hemoglobin A1c; FBG: fasting blood glucose; 2hPG: 2 h plasma glucose; CRE: serum creatinine. ∗p < 0.05 was considered statistically significant.